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Cycloheximide is the most common protein synthesis inhibitor, and is believed to speciﬁcally inhibit
the cytoplasmic protein synthesis. Here we demonstrate that cycloheximide induces internalization
and redistribution of EGF receptor to early endosomes in HeLa cells independent of receptor
tyrosine phosphorylation, but dependent on p38 MAPK activity. Degradation of EGF receptor or
its downstream effectors was not observed. EGF-induced activation of ERK1/2 was inhibited upon
pre-treatment with cycloheximide, but did not activate JNK. The observed effects of treatment with
cycloheximide alone are signiﬁcant and therefore results involving the use of cycloheximide for
inhibition of protein synthesis must be interpreted with caution.
Structured summary of protein interactions:
EEA1 and EGFR colocalize by ﬂuorescence microscopy (View interaction).
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cycloheximide represents the most common laboratory reagent
used to block protein synthesis and is widely used in studies
regarding trafﬁcking of EGFR [1,2]. Cycloheximide was originally
isolated from Streptomyces griseus and identiﬁed as an inhibitor
of eukaryotic translation blocking the translational elongation
phase [3–5]. Cycloheximide binds the ribosomal E-site and inhibits
eEF2-mediated translocation [6,7]. It is widely used to clarify if de
novo synthesis of proteins is required for a speciﬁc biological pro-
cess, and is commonly used to avoid new synthesis of proteins in
cell signaling and degradation studies. The use of cycloheximide
in this type of studies depends upon the assumption that it is a
speciﬁc inhibitor of protein synthesis and does not have other side
effects. However, unspeciﬁc effects of cycloheximide have previ-
ously been reported, e.g. inhibition of DNA synthesis [8], interfer-
ence with ion absorption [9], and amino acid uptake [10,11].
These effects of cycloheximide have in part been explained by
direct or indirect effects of the protein synthesis block, though
others have found that the effects of cycloheximide on most other
processes are separate from its effect on protein synthesis [12].chemical Societies. Published by E
nology, Institute for Cancer
spital, Montebello, 0310 Oslo,
old).Here we report that cycloheximide, through activation of p38
MAPK, induces ligand independent internalization of unphosphor-
ylated EGF receptor. Preincubation of cycloheximide leads to
reduced level of cell surface EGF receptors and reduced EGF-
induced activation of ERK1/2 MAPK. Our results demonstrate that
pretreatment with cycloheximide can potently inﬂuence the
experimental conditions and thus the interpretation of the results
in studies of EGF receptor.
2. Materials and methods
2.1. Cell culture
HeLa-P cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM; PAA) supplemented with 10% fetal bovine serum
(FBS; HyClone), penicillin and streptomycin. In all experiments,
cells were starved over night in OptiMem (Life Technologies, NY).
Cells were routinely tested for mycoplasma (Venor GeM, Minerva
Biolabs, Berlin).
2.2. Reagents
Murine EGF from submaxillary glands was obtained from
Sigma–Aldrich (MO) and used at a ﬁnal concentration of 50 ng/ml.
Cycloheximide was purchased from Sigma–Aldrich and dissolved
in ethanol to a stock concentration of 20 mg/ml and further dilutedlsevier B.V. All rights reserved.
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ogies, NY). SB203580 was obtained from Merck (Germany). The
following primary antibodies were used: rabbit anti-phospho-
ERK1/2 (p42/p44), -phospho-p38, -phospho-JNK1/2, and -b-Tubu-
lin (Cell Signaling Technology, MA), mouse anti-ERK2 (Santa Cruz
Biotechnology, CA), sheep anti-EGF receptor (Fitzgerald Industries,
MA), mouse anti-EGFR (extracellular, clone EGFR.1; Thermo Fischer
Scientiﬁc, MA), and rabbit anti-EEA1 (Cell Signaling Technology).
Rabbit anti-pY1068, -pY1086 and pY1148 EGF receptor antibodies
were kindly provided by A.J. Wong (Stanford University Medical
Center, Stanford, CA). Rabbit anti-pY1173 and -pY992-EGF receptor
antibodies have been described earlier [13]. Secondary HRP-cou-
pled goat anti-rabbit IgG and rabbit anti-mouse and sheep IgGwere
obtained from Dako (Denmark) whereas DyLight549 donkey
anti-sheep and Alexa488 donkey anti-human were obtained from
Jackson ImmunoResearch (PA).
2.3. Flow cytometry
HeLa-P cells grown in 6-well plates were starved over night in
OptiMem before exposure to cycloheximide and EGF for the indi-
cated time. Cells were washed in ice cold PBS, trypsinated and
transferred to 96-well plates. Cells were ﬁxed in 4% paraformalde-
hyde (PFA; Electron Microscopy Sciences) in PBS for 15 min at RT.
Cells were incubated in human c-globulin (1 mg/ml) in PBS for
10 min at RT before staining with mouse anti-EGFR, followed by
RPE-coupled goat anti-mouse IgG (Southern Biotech, AL). Un-
stained cells and cells stained with mouse IgG (Dako, Denmark)
and RPE-coupled goat anti-mouse IgG were used as controls. Cells
were analyzed using FACSCanto II (Becton Dickinson, CA) and data
was processed using FlowJo (Three Star, OR) and Adobe Illustrator
(Adobe Systems, CA).
2.4. Confocal microscopy
HeLa-P cells grown on cover slips were starved in OptiMem
over night, pretreated with or without cycloheximide, followed
by EGF-stimulation. In some experiments, cells were pre-treated
with the p38 MAPK inhibitor SB203580 before exposure to cyclo-
heximide. Cells were ﬁxed in 4% paraformaldehyde (Electron
Microscopy Sciences, PA) in PBS for 15 min on ice before permeabi-
lized in PEM buffer (0.1 M PIPES, pH 7.0, 2 mM EGTA, 1 mM
MgSO4) containing 0.2% IGEPAL CA-630 (Sigma) for 5 min on ice.
Cells were immunostained with mouse anti-EGFR and rabbit
anti-EEA1 antibodies followed by secondary DyLight594 donkey
anti-mouse and DyLight649 donkey anti-rabbit (Jackson Immuno-
Research). Cells were mounted with anti-fading mounting medium
(Dako) containing Hoechst (1 lg/ml; Merck) and examined with a
Zeiss LSM 710 confocal laser-scanning microscope (Carl Zeiss, Jena,
Germany). A Zeiss Plan-Apochromat 63/1.40 Oil DIC M27 objec-
tive was used. Image processing was performed with basic soft-
ware ZEN 2009, Image J (Carl Zeiss) and Photoshop/Illustrator
(Adobe Systems).
2.5. Western immunoblotting analysis
Cells were starved in OptiMem over night before exposure to
cycloheximide and EGF. Cells were lysed in Tris lysis buffer, pH
6.8 (62.7 mM Tris–HCl, 10% (v/v) glycerol, 2.3% (w/v) SDS, 5% b-
mercaptoethanol, protease inhibitor mixture (Complete Mini,
Roche) and phosphatase inhibitor mixture (PhosSTOP, Roche)). Ly-
sates were incubated at 95 C for 10 min, cleared by centrifugation
(10,000xg, 5 min) and protein concentrations were determined
with the Bio-Rad DC protein assay. Samples (5–20 lg/lane) were
run on 10% or 12% SDS-polyacrylamide gels (BioRad) and trans-
ferred to PVDF membranes (Millipore). The membranes wereblocked in 5% non-fat dry milk or 5% BSA (Sigma–Aldrich) in TBST,
and incubated over night at 4 C with antibody diluted in 5% non-
fat dry milk or 5% BSA in TBST. HRP-conjugated anti-rabbit, -
mouse, and -sheep IgG antibodies incubated for 60 min at RT were
used followed by detection using ECL or ECL Plus (GE Healthcare,
NJ).
2.6. Statistical analysis
Statistical signiﬁcance of differences between groups was deter-
mined using the Student’s one-tailed t-test. Analyses were per-
formed in GraphPad Prism. P values less than 0.05 were
considered statistically signiﬁcant.3. Results
3.1. Cycloheximide induces EGF receptor internalization
In previous experiments where we pretreated HeLa cells with
cycloheximide prior to ligand stimulation, we noticed a reduced
capacity in response to EGF in cycloheximide-pretreated cells com-
pared to untreated cells. To address if cycloheximide has an impact
on EGF receptor cell surface expression and internalization, we
measured the levels of EGF receptor at the cell surface at different
time points upon cycloheximide treatment and compared with
EGF-stimulation (Fig. 1A). Cells were ﬁxed, stained with an anti-
body speciﬁc for the extracellular domain of EGF receptor and ana-
lyzed by ﬂow cytometry. Stimulation with EGF for 1 h induced, as
expected, a robust EGF receptor internalization with receptor cell
surface levels reduced by approximately 70% (Fig. 1A,B). A similar
effect was observed after treatment with a moderate dose of cyclo-
heximide (10 lg/ml) for 1 h, where the EGF receptor amount was
reduced by 62% (Fig. 1A,B). Pretreatment with 10–20 lg/ml cyclo-
heximide for 1 h or longer is usual in laboratories [14], and concen-
trations as high as 60 lg/ml have been used [2]. When we
compared pretreatment with different concentrations of cyclohex-
imide for 1 h, we noticed that EGF receptor internalization was
detectable at concentrations as low as 0.1 lg/ml with an approxi-
mately 20% reduction in cell surface EGF receptor levels (Fig. 1C).
Cycloheximide-induced internalization of EGF receptor was de-
tected after 10 min (Fig. 1D). EGF receptor internalized by cyclo-
heximide treatment was found to localize to early endosomes, as
shown by confocal microscopy and co-localization with the early
endosome marker EEA1 (Fig. 2).
In order to conﬁrm that the reduced level of EGF receptors at
the plasma membrane is not due to a reduction in the total level
of EGF receptor per se, as a direct effect of the protein synthesis
inhibition, we analyzed the receptor levels by Western immuno-
blotting. No reduction in total EGF receptor level was observed
after 1 h preincubation with cycloheximide alone or stimulated
with EGF (Fig. 3A).
3.2. Cycloheximide-induced internalization of EGFR is independent of
tyrosine phosphorylation
In order to characterize the cycloheximide-induced effects on
EGF receptor and to compare with EGF-induced internalization,
we analyzed possible induction of receptor tyrosine phosphoryla-
tion by Western immunoblotting. Tyrosine phosphorylation of
EGF receptor was detected after 15 and 30 min incubation with
EGF (Fig. 3B). In contrast, cycloheximide did not induce tyrosine
phosphorylation of EGF receptor (Fig. 3B). This observation is in
line with previous results from other stress induced activators of
EGF receptor, e.g. exposure to UV irradiation [15] and inﬂamma-
tory cytokines [16].
Fig. 1. Cycloheximide induces internalization of EGF receptor. (A, B) HeLa cells were incubated with EGF (50 ng/ml) for 1 h, cycloheximide (CHX; 10 lg/ml) for 1 h, or
cycloheximide (1 h) followed by EGF (1 h). Cell surface expression of EGF receptor was analyzed by ﬂow cytometry. (B) The values represent mean MFI of EGF receptor
relative to MFI of EGF receptor in unstimulated cells (n = 4, p = 0.0002, error bars represent SEM). (C) Cells were treated with different concentrations of cycloheximide and
analyzed as described in A. (D) Cells were treated with cycloheximide (10 lg/ml) for the indicated time before analysis as described in A.
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activation of ERK1/2
Since pretreatment with cycloheximide induced internalization
of EGF receptor and reduced level of EGF receptors at the plasma
membrane, we analyzed how EGF-induced activation of EGF recep-
tor and ERK1/2 were affected upon pretreatment with cyclohexi-
mide prior to EGF. EGF induced strong phosphorylation of both
EGF receptor and ERK1/2, which was detected after 15 and
30 min with continuous EGF stimulation (Fig. 3C,D). Pretreatment
with cycloheximide (10 lg/ml) for 1 h led to reduced EGF-induced
activation of EGF receptor and ERK1/2 (Fig. 3C, quantiﬁcation in D).
The observed reduction in ERK1/2 activation in the cycloheximide-
pretreated cells was not due to reduced levels of total EGFR and
ERK (Fig. 3C).
3.4. Cycloheximide-induced internalization of EGFR is dependent of
p38 MAPK
It has previously been shown that p38 kinase regulates EGF
receptor downregulation and cellular migration [22], and can pro-
mote ligand-independent EGF receptor internalization in response
to cellular stress [16,17]. Treatment with UV irradiation or inﬂam-
matory cytokines [16] and anisomycin [17] initiate p38-dependent
EGF receptor internalization. Short time exposure to cycloheximide
induced phosphorylation of p38, and after 10 min of treatment thep38-activation was comparable to EGF- and ultra-violet C (UVC)-
induced activation (Fig. 4A). To determine whether p38 activity
also is required for cycloheximide-induced internalization of EGF
receptor, cells were exposed to cycloheximide for 1 h after incuba-
tion with a p38-speciﬁc inhibitor (SB203580). Preincubation with
low concentration of SB203580 (3 lM) partially blocked cyclohex-
imide-induced internalization of EGF receptor, as detected by ﬂow
cytometry (Fig. 4B,C). This inhibition of cycloheximide-induced
internalization of EGF receptor was also observed by confocal
microscopy, where pretreatment with SB203580 reduced the
cycloheximide-induced vesicular localization of EGF receptor and
also inhibited the co-localization with EEA1 (Fig. 4D).
When another stress-induced kinase, the c-Jun NH2-terminal
kinase (JNK) was studied, we noticed that while EGF induced a pro-
found activation of JNK, activation by cycloheximide was not de-
tected (Fig 4D). Furthermore, stress-activation by UV also
induced activation of JNK (Fig. 4D). This indicates that cyclohexi-
mide represents a stress stimulus which is different from JNK-acti-
vating stresses like UV irradiation, hyperosmolarity, heat shock
and exposure to different cytokines.
4. Discussion
Pretreatment with cycloheximide in experimental studies such
as receptor signaling, trafﬁcking and degradation is commonly
used, although reports of its unspeciﬁc effects not related to
Fig. 2. Localization of cycloheximide-induced EGF receptor to early endosomes. HeLa cells were treated with EGF (50 ng/ml) or cycloheximide (CHX 10 lg/ml) for 1 h, ﬁxed
and stained with mouse anti-EGF receptor (red) and rabbit anti-EEA1 (green). Nuclear DNA was visualized by Hoechst (blue). Co-localization of EGFR and EEA1 is indicated by
yellow color. Representative images are shown. Bars, 10 lm and 2.9 lm (zoom).
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Fig. 3. Cycloheximide-induced internalization of EGFR is independent of tyrosine phosphorylation. (A) Cells were treated with EGF for 15 and 30 min or pretreated with
cycloheximide (CHX) for 1 h followed by EGF for 15 and 30 min. Cells were lysed and analyzed by Western immunoblotting with anti-EGF receptor. (B) Cells were treated
with CHX or EGF for the indicated time, lysed and analyzed by Western immunoblotting with anti-pY1173 (pY1173), anti-pY992 (pY992), anti-pY1068 (pY1068), anti-
pY1086 (pY1068) and anti-pY1148 (pY1148) EGF receptor antibodies. (C and D) Cells were treated as described in (A) and immunoblottet with anti-pY1173-EGF receptor, -
EGF receptor and -phospho-ERK1/2. (D) The values represent mean optical density relative to loading control (n = 4, p = 0.0190 and 0.0435 (⁄ and ⁄⁄, respectively for pEGFR),
p = 0.0089 and 0.0205 (⁄ and ⁄⁄, respectively for pERK1/2.)). Error bars represent SEM. Anti-b-tubulin, anti-EGFR and anti-ERK2 antibodies were used as loading control. Each
Western immunoblot is representative of 3 independent experiments.
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are preincubated with cycloheximide for one to several hours be-
fore starting the experiment. When studying EGF receptor signal-
ing in HeLa cells, we noticed that cycloheximide has signiﬁcant
impact on trafﬁcking of and signaling from EGF receptor. Cyclohex-
imide induced internalization of EGF receptor at concentrations
comparable to those frequently used [1,2]. Internalization of EGF
receptor was detectable with as low as 0.1 lg/ml cycloheximide
and as early as 10 min upon cycloheximide addition. The reduced
levels of EGF receptor at the cell surface could not be explained
by protein synthesis inhibition of the receptor, since the total level
of EGF receptors was not reduced.
The reduced level of EGF receptors at the cell surface upon
cycloheximide treatment led to decreased signal reception as seen
by reduced EGF-induced activation of the MAPKs ERK1/2 (Fig. 3C).
Cycloheximide effects on the MAPK signaling pathway has been re-
ported earlier [18]. However, in this latter study cycloheximide in-duced a small increase in ERK1/2 activation. The cycloheximide-
induced effects on MAPK ERK1/2 were explained by inhibition of
the translation and activity of MAPK phosphatase-1 (MKP-1) due
to increased release of arachidonic acid. We were unable to detect
cycloheximide-induced activation of ERK1/2 in our cell system.
This can be due to cell type differences in arachidonic acid release
and cPLA2 activity. Nevertheless this illustrates the numerous cel-
lular effects of cycloheximide.
The MAPK p38 is associated with cellular stress responses and
apoptosis [19,20], and cycloheximide is added to an extensive list
of stresses that induce activation of this stress-induced kinase.
Interestingly, cycloheximide did not activate JNK, another type of
stress-induced kinase. This is in contrast to the strong activation
of different JNK isoforms by exposure to e.g. cytokines or UV irra-
diation [21].
In this study we have focused on the effects of cycloheximide on
EGF receptor signaling, trafﬁcking and degradation in HeLa cells,
Fig. 4. Cycloheximide-induced internalization of EGFR is dependent of p38 MAPK, but not JNK. (A) Cells were treated with cycloheximide (CHX), EGF or UV for the indicated
time and analyzed by Western immunoblotting with anti-phospho-p38. (B and C) Flow cytometry analysis of CHX-induced internalization of EGF receptor with or without
pretreatment with the p38-speciﬁc inhibitor SB203580. (C) The values represent mean MFI of EGF receptor relative to MFI of EGF receptor in unstimulated cells (n = 3,
p = 0.025, error bars represent SEM). (D) Cells were pretreated (d–f) or not (a–c) with SB203580 (3 lM) for 45 min followed by incubation with CHX (10 lg/ml) for 1 h, ﬁxed
and stained with mouse anti-EGF receptor (EGFR; a,d; red) and rabbit anti-EEA1 (b,e; green). Nuclear DNA was visualized by Hoechst (c,f; blue). Co-localization of EGFR and
EEA1 (c,f) is indicated by yellow color. Representative images are shown. Bars, 10 lm and 2.9 lm (zoom). (E) Cells were treated as described in (A) and immunoblotted with
anti-phospho-JNK. Anti-b-tubulin was used as loading control. Each Western immunoblot is representative of 3 independent experiments.
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M.P. Oksvold et al. / FEBS Letters 586 (2012) 3575–3581 3581and potential effects on other pathways cannot be ruled out. How-
ever, the strong effects of cycloheximide alone or in combination
with EGF treatment in HeLa cells are of such an impact that data
obtained using cycloheximide for inhibition of protein synthesis
must be interpreted with caution.Acknowledgments
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